Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This research study is studying an immune-based cancer drug as a possible treatment for
prostate cancer.
The drug involved in this study is:
-Nivolumab